Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royal Bank of Canada (NY:RY)

205.36 -2.26 (-1.09%)
Streaming Delayed Price Updated: 2:05 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royal Bank of Canada

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
News headline image
Why Veeva Systems (VEEV) Stock Is Up Today
What Happened? Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 3.8% in the afternoon session after the company announced tha... 
Via StockStory
Topics Artificial Intelligence
News headline image
Royal Bank Of Canada Q2 Earnings Call Highlights ↗
Royal Bank Of Canada (NYSE:RY) reported fiscal second-quarter earnings of CAD 5.5 billion, with adjusted earnings of CAD 5.6 billion, as management highlighted strong results across capital markets,... 
Via MarketBeat
Topics Earnings World Trade
News headline image
Are Wall Street Analysts Predicting FactSet Research Systems Stock Will Climb or Sink?
As FactSet Research Systems has notably lagged the broader market over the past 52 weeks, Wall Street analysts maintain a cautious outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs Supply Chain
News headline image
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance ↗
Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and... 
Via MarketBeat
News headline image
M&T Bank Stock: Is Wall Street Bullish or Bearish?
M&T Bank has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Kymera Therapeutics Stays on Track With KT-621 Trials, Teases IRF5 Data ↗
Kymera Therapeutics (NASDAQ:KYMR) executives said the company remains on track with key clinical timelines for its lead degrader programs, including KT-621 in atopic dermatitis and asthma, while... 
Via MarketBeat
News headline image
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst ↗
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within... 
Via MarketBeat
News headline image
Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts ↗
Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare... 
Via MarketBeat
News headline image
A Canadian Energy Stock Ready to Bring in the Heat in 2026 ↗
Cenovus Energy is a strong buy in 2026 for its massive free cash flow and refining power. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The Best Canadian Stocks to Own During a Trade War ↗
Three Canadian stocks are the top buys for investors seeking built-in defences during a trade war. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
News headline image
Do Wall Street Analysts Like Air Products and Chemicals Stock?
Despite Air Products and Chemicals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects. 
Via Barchart.com
Topics ETFs Supply Chain
News headline image
3 Market-Beating Stocks on Our Watchlist
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Stocks That Could Turn $100,000 Into $1 Million ↗
Two stocks and an income-and-growth strategy could turn $100,000 into a seven-figure fortune over time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference ↗
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC... 
Via MarketBeat
News headline image
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near ↗
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president... 
Via MarketBeat
News headline image
Cytokinetics Says MYKORZO Launch Tops Expectations as HCM Data Draws Praise ↗
Cytokinetics (NASDAQ:CYTK) executives said the commercial launch of MYKORZO is tracking ahead of internal expectations, while also highlighting positive physician feedback on the drug’s label, REMS... 
Via MarketBeat
News headline image
Are Wall Street Analysts Predicting Cboe Global Markets Stock Will Climb or Sink?
Cboe Global Markets has considerably outperformed the broader market over the past 52 weeks, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects. 
Via Barchart.com
Topics Derivatives ETFs
News headline image
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential ↗
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent... 
Via MarketBeat
News headline image
Corbus Pharmaceuticals Teases Key ASCO Cancer Data, Late-Summer Obesity Readout ↗
Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first... 
Via MarketBeat
News headline image
5 Must-Read Analyst Questions From RBC Bearings’s Q1 Earnings Call
RBC Bearings delivered first quarter results that surpassed Wall Street’s revenue and non-GAAP profit expectations, but the market responded negatively. Mana... 
Via StockStory
Topics Earnings
News headline image
Sprout Social and Veeva Systems Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is... 
Via StockStory
Topics Artificial Intelligence
News headline image
Asana, Atlassian, and BlackLine Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is... 
Via StockStory
Topics Artificial Intelligence
News headline image
Are Wall Street Analysts Predicting IQVIA Holdings Stock Will Climb or Sink?
While IQVIA Holdings has lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects. 
Via Barchart.com
Topics ETFs
News headline image
Dear F5 Stock Fans, Mark Your Calendars for May 28
Upcoming analyst day is likely to provide further insights on AI-driven growth momentum. 
Via Barchart.com
Topics Artificial Intelligence Earnings
News headline image
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference ↗
CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder... 
Via MarketBeat
Topics Initial Public Offering
News headline image
1 Top Dividend Stock to Buy and Hold for 10 Years ↗
A monthly dividend stock with assured demand and business growth fits a 10-year investment horizon. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
The #1 Stock I’d Keep Forever Inside a TFSA ↗
A renewable energy powerhouse with visible business growth potential is an ideal lifelong investment for a TFSA. 
Via The Motley Fool
Topics Artificial Intelligence Retirement
News headline image
Lattice Semiconductor (LSCC) Shares Skyrocket, What You Need To Know
What Happened? Shares of semiconductor designer Lattice Semiconductor (NASDAQ:LSCC) jumped 9.7% in the afternoon session after CEO Ford Tamer's presentation ... 
Via StockStory
Topics Artificial Intelligence Government
News headline image
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances ↗
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics... 
Via MarketBeat
Topics Intellectual Property
News headline image
Why Are GE Aerospace (GE) Shares Soaring Today
What Happened? Shares of industrial conglomerate GE Aerospace (NYSE:GE) jumped 5% in the afternoon session after the company secured a U.S. Air Force contrac... 
Via StockStory
Topics Bonds Economy
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.